Department of Pathophysiology, Prostate Diseases Prevention and Treatment Research Center, School of Basic Medical Sciences, Jilin University, Changchun, Jilin 130021, P.R. China.
Department of Cardiovascular Medicine, China‑Japan Union Hospital, Jilin University, Changchun, Jilin 130021, P.R. China.
Oncol Rep. 2020 Feb;43(2):591-600. doi: 10.3892/or.2019.7439. Epub 2019 Dec 17.
Mutation of the p53 tumor suppressor frequently occurs in lung cancer, and can be as high as 75‑90% in small‑cell lung cancer. Mutant p53 (mtp53) can inhibit the wild‑type p53 protein, disrupting its tumor suppressor functions. In addition, mutant p53 often acquires the functions of an oncogene. Post‑translational modification of the p53 protein is important for its transcriptional and tumor suppressive functions. We previously revealed that high levels of mutant p53 expression were associated with reduced expression of the deacetylation enzyme sirtuin 3 (SIRT3) in lung cancer tissues. Given this negative correlation between p53 and SIRT3 expression, and given that SIRT3 is a deacetylase, we speculated that SIRT3 participates in the post‑translational modification of mutant p53, regulating its stability and function, thereby inhibiting the growth of lung cancer cells. Light microscopy, MTT and flow cytometric assays revealed that SIRT3 overexpression inhibited growth and promoted apoptosis in NCI‑H446 human small cell lung cancer cells. SIRT3 overexpression also resulted in necroptosis, and this could be partially reversed following cell treatment with the necroptosis inhibitor necrostatin‑1 (Nec‑1), which could restore certain cells to survive. Western blotting assays revealed that SIRT3 overexpression resulted in the reduced expression and half‑life of mutant p53, indicating that SIRT3 decreases mutant p53 stability. Proteasome inhibitor experiments revealed that the decrease in mutant p53 stability was a result of increased proteasomal degradation of the protein. Immunoprecipitation studies revealed that ubiquitination of mutant p53 was elevated in SIRT3‑overexpressing cells, indicating that SIRT3 affected ubiquitination‑mediated protein degradation. In the present study, it was therefore revealed that SIRT3 can inhibit the growth of human small‑cell lung cancer cells by promoting apoptosis and necroptosis. It was also revealed that SIRT3 expression could regulate the stability of mutant p53 by controlling ubiquitination‑mediated proteasomal degradation of the protein. SIRT3 expression may therefore play an important role in the growth of mutant p53‑associated lung cancer.
抑癌基因 p53 的突变在肺癌中频繁发生,在小细胞肺癌中可高达 75-90%。突变型 p53(mtp53)可以抑制野生型 p53 蛋白,破坏其肿瘤抑制功能。此外,突变型 p53 通常获得癌基因的功能。p53 蛋白的翻译后修饰对其转录和肿瘤抑制功能很重要。我们之前发现,肺癌组织中高表达突变型 p53 与去乙酰化酶 SIRT3 的表达降低有关。鉴于 p53 和 SIRT3 表达之间存在这种负相关,并且 SIRT3 是一种去乙酰化酶,我们推测 SIRT3 参与了突变型 p53 的翻译后修饰,调节其稳定性和功能,从而抑制肺癌细胞的生长。光学显微镜、MTT 和流式细胞术检测结果显示,SIRT3 过表达可抑制 NCI-H446 人小细胞肺癌细胞的生长并促进其凋亡。SIRT3 过表达还导致坏死性凋亡,而用坏死性凋亡抑制剂 necrostatin-1(Nec-1)处理细胞后,这种凋亡可以部分逆转,从而使部分细胞恢复存活。Western blot 检测结果显示,SIRT3 过表达导致突变型 p53 表达和半衰期降低,表明 SIRT3 降低了突变型 p53 的稳定性。蛋白酶体抑制剂实验显示,突变型 p53 稳定性降低是由于该蛋白的蛋白酶体降解增加所致。免疫沉淀研究表明,SIRT3 过表达细胞中突变型 p53 的泛素化水平升高,表明 SIRT3 影响了泛素化介导的蛋白降解。因此,本研究揭示了 SIRT3 通过促进细胞凋亡和坏死性凋亡来抑制人小细胞肺癌细胞的生长。还揭示了 SIRT3 通过控制蛋白的泛素化介导的蛋白酶体降解来调节突变型 p53 的稳定性。因此,SIRT3 表达可能在与突变型 p53 相关的肺癌生长中发挥重要作用。